Centre Hospitalier De Chauny

Chauny 9 trials 4 recruiting

9 Registered trials

4 Currently recruiting

Organisation

Centre Hospitalier De Chauny

Location

Chauny, France

Identifier

ORG-100048745

Address

94 Rue Anciens Combattants Afn Tom, 02300, France

Departments

Centre de Coordination de Cancérologie
oncology
Pneumologie
Service de Pneumologie

Clinical trials at this site (9)

Search interface

PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte… Recruiting

2024-515945-40-00 Non small cell lung cancer 10 2022-05-02
CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co… Recruiting

2024-518578-15-00 Is to demonstrate a non inferior efficacy of azithromyc 5 2018-02-05
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended

2022-503071-28-00 Squamous Non-small cell Lung Cancer 5 2023-08-31
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Non small cell lung cancer 5 2018-05-02